<DOC>
	<DOCNO>NCT00562913</DOCNO>
	<brief_summary>Study access safety , level drug blood tumor effect sorafenib dose daily combine Cyclophosphamide Doxorubicin cancer patient</brief_summary>
	<brief_title>Phase I Study Sorafenib Dosed Continuously With Cyclophosphamide Doxorubicin</brief_title>
	<detailed_description />
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>At least 18 year old Advanced histological cytological documentation cancer lifeexpectancy least 12 week able swallow pill ECOG status 0,1 2 adequate bone marrow liver renal function &gt; NYHA Class 2 CHF Serious myocardial dysfunction , symptomatic coronary artery disease ( MI 6 month prior study entry allow ) History organ allograft uncontrolled hypertension renal dialysis Bleeding event/hemorrhage within 4 week study treatment major surgery within 4 week study treatment Previous exposure doxorubicin anthracyclines exceed maximum lifetime cumulative dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin</keyword>
</DOC>